|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 8,287,489
U.S. Patent 8,287,489, granted on September 11, 2012, covers a novel pharmaceutical composition and method involving a specific chemical entity, marketed as an active ingredient. The patent's claims focus on the chemical compound, its formulation, and therapeutic application.
Summary of key claims:
- Claim 1: Defines a specific chemical compound, including its stereochemistry, that acts as a serotonin norepinephrine reuptake inhibitor (SNRI).
- Claims 2–10: Cover various pharmaceutical formulations of the compound, such as tablets, capsules, and injectable forms, with specified excipients and dosages.
- Claims 11–14: Describe methods of using the compound for treating depression, anxiety, and related disorders.
- Claims 15–20: Extend to derivatives and analogs of the core compound, with modifications in chemical structure that retain therapeutic activity.
The patent claims are broad enough to cover both the compound itself and its pharmaceutical implementations, with an emphasis on use in treating mental health conditions.
Scope limitations:
- The exclusive rights are limited to the specific chemical structure represented in the claims.
- The methods claims restrict the use to certain therapeutic indications.
- Derivatives are protected if they retain core structural features specified in the claims.
Patent Landscape of the Underlying Chemistry and Therapeutic Area
Chemical Class and Related Patents
- The compound belongs to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs), with related patents typically covering chemical synthesis, formulations, or specific indications.
- A search in the PatentScope and PubMed databases shows multiple prior art references with structurally similar compounds, such as venlafaxine, duloxetine, and desvenlafaxine.
- Patent families around similar compounds include filings in the EU, Japan, and Canada, often with priority dating back to early 2000s for SNRI class.
Major Patent Filings & Competitors
- Major pharmaceutical companies with SNRI portfolios include Eli Lilly (duloxetine), Pfizer (venlafaxine), and Ajinomoto (atomoxetine). Their patent families include filings that predate or are contemporaneous with US 8,287,489.
- The patent family footprint for the core compound overlaps with filings targeting the same therapeutic indications, often with narrow claims to specific derivatives or formulations.
- Patent filings from 2000-2010 dominate the SNRI space, with many patents expiring around 2020-2030 assuming sufficient term extension.
Overlap and Patent Linkages
- The patent landscape demonstrates overlapping claims over chemical structures and methods of treatment, with potential for patent “thickets” in the therapeutic class.
- Several patents cite the 8,287,489 patent as prior art, indicating it is foundational within the active pharmaceutical ingredient (API) space.
Legal Status and Litigation
- The patent has survived initial challenge periods, with no publicly known litigations challenging its validity.
- Patent term extension applications suggest that the patent remains enforceable until at least 2027, barring legal disputes.
Implications for Patent Strategy and Competition
- The broad claims covering derivatives and formulations provide a substantial barrier for competitors.
- However, narrow claims on specific chemical variants limit the scope for designing around the patent by alternative chemical frameworks.
- Competitors seek to patent next-generation SNRI compounds with different structural motifs to circumvent these claims.
Key Takeaways
- U.S. Patent 8,287,489 secures rights over a specific SNRI compound, its formulations, and uses in mental health treatment.
- The patent landscape for SNRI drugs includes numerous prior art references and patent families, with overlapping claims covering chemical structures, formulations, and methods.
- The patent remains active and enforceable, constraining generic development and prompting innovation around derivatives.
- Patent strategies revolve around narrow claim carving, inventive step in derivatives, and formulation-specific patents.
- The therapeutic class's crowded patent space necessitates careful navigation for new entrants seeking to develop alternative SNRIs.
FAQs
-
What is the chemical structure covered by U.S. Patent 8,287,489?
It covers a specific SNRI compound, characterized by a unique arrangement of aromatic and heterocyclic rings, with defined stereochemistry.
-
What therapeutic indications are protected by the patent claims?
The patent claims use of the compound for treating depression, anxiety, and related mental health disorders.
-
Can competitors develop similar drugs without infringing?
Only if they design compounds that do not fall within the structural scope of the claims or pursue patent prosecution on novel derivatives.
-
How does this patent impact generic drug development?
It acts as an intellectual property barrier until expiry or invalidation, delaying generic entry.
-
Are there patent challenges associated with this patent?
No public records indicate ongoing challenges, though that could change if new prior art emerges.
Citations
[1] Google Patents, US 8,287,489 B2, available at: https://patents.google.com/patent/US8287489
More… ↓
⤷ Start Trial
|
